铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展

doi:10.3760/cma.j.cn371439-20231229-00040

国际肿瘤学杂志 ›› 2024, Vol. 51 ›› Issue (4): 239-244.doi: 10.3760/cma.j.cn371439-20231229-00040

铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展

王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛()

云南省肿瘤医院（昆明医科大学第三附属医院）骨科，昆明 650118

收稿日期:2023-12-29 修回日期:2024-03-01 出版日期:2024-04-08 发布日期:2024-05-10
通讯作者: 袁涛，Email：yuantao2015@hotmail.com
作者简介:王子豪和王宇对本文有同等贡献
基金资助:
云南省科技厅科技计划(202201AT070012);昆明医科大学博士研究生创新基金(2023B10)

Research progress on the molecular mechanism and related treatments of ferroptosis in osteosarcoma

Wang Zihao, Wang Yu, Yang Xin, He Yi, Mo Xingkui, Yuan Tao()

Department of Orthopaedics， Yunnan Cancer Hospital （Third Affiliated Hospital of Kunming Medical University）， Kunming 650118， China

Received:2023-12-29 Revised:2024-03-01 Online:2024-04-08 Published:2024-05-10
Contact: Yuan Tao， Email：yuantao2015@hotmail.com
About author:Wang Zihao and Wang Yu are contributed equally to the article
Supported by:
Science and Technology Plan of Yunnan Provincial Department of Science and Technology(202201AT070012);Doctoral Student Innovation Fund Project of Kunming Medical University(2023B10)

摘要/Abstract

摘要：

骨肉瘤作为常见的原发恶性骨肿瘤之一，因其较差的预后及较单一的治疗方式，使得目前临床对骨肉瘤患者的治疗已达到瓶颈期。然而，越来越多的研究发现铁死亡作为一种新型的细胞死亡方式，或可在骨肉瘤的治疗中发挥重要作用。近年来，随着对铁死亡相关机制及分子通路研究的愈加深入，其在骨肉瘤中的特异性治疗策略也相继得以验证，这有望为骨肉瘤患者的临床治疗提供新思路。

关键词: 骨肉瘤, 铁死亡, 活性氧, 肿瘤治疗方案

Abstract:

Osteosarcoma is one of the most common primary malignant bone tumors， which has reached a "bottleneck" in the current clinical treatment of patients with osteosarcoma due to its poor prognosis and lack of therapeutic modalities. Recently， more and more researches have found that ferroptosis， as a novel cell death modality， may play an important role in osteosarcoma treatment. In recent years， with more in-depth studies on the mechanisms and molecular pathways related to ferroptosis， its specific therapeutic strategies in osteosarcoma have also been validated， which is expected to provide new ideas for the clinical treatment of osteosarcoma patients.

Key words: Osteosarcoma, Ferroptosis, Reactive oxygen species, Antineoplastic protocols

王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛. 铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.

Wang Zihao, Wang Yu, Yang Xin, He Yi, Mo Xingkui, Yuan Tao. Research progress on the molecular mechanism and related treatments of ferroptosis in osteosarcoma[J]. Journal of International Oncology, 2024, 51(4): 239-244.

图/表 1

参考文献 40

[1]	Lee JA, Lim J, Jin HY, et al. Osteosarcoma in adolescents and young adults[J]. Cells, 2021, 10(10): 2684. DOI: 10.3390/cells10102684.
[2]	Cole S, Gianferante DM, Zhu B, et al. Osteosarcoma: a surveillance, epidemiology, and end results program-based analysis from 1975 to 2017[J]. Cancer, 2022, 128(11): 2107-2118. DOI: 10.1002/cncr.34163.
[3]	Dos Santos AF, Fazeli G, Xavier da Silva TN, et al. Ferroptosis: mechanisms and implications for cancer development and therapy response[J]. Trends Cell Biol, 2023, 33(12): 1062-1076. DOI: 10.1016/j.tcb.2023.04.005.
[4]	Liu X, Du SW, Wang SD, et al. Ferroptosis in osteosarcoma: a promising future[J]. Front Oncol, 2022, 12: 1031779. DOI: 10. 3389/fonc.2022.1031779.
[5]	Lei T, Qian H, Lei PF, et al. Ferroptosis-related gene signature associates with immunity and predicts prognosis accurately in patients with osteosarcoma[J]. Cancer Sci, 2021, 112(11): 4785-4798. DOI: 10.1111/cas.15131.
[6]	Chen WK, Li ZG, Yu NC, et al. Bone-targeting exosome nanoparticles activate Keap1/Nrf2/GPX4 signaling pathway to induce ferroptosis in osteosarcoma cells[J]. J Nanobiotechnology, 2023, 21(1): 355. DOI: 10.1186/s12951-023-02129-1.
[7]	Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition[J]. Nature, 2017, 551(7679): 247-250. DOI: 10.1038/nature24297.
[8]	Rochette L, Dogon G, Rigal E, et al. Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis[J]. Int J Mol Sci, 2022, 24(1): 449. DOI: 10.3390/ijms24010449.
[9]	Guo WT, Wang X, Lu B, et al. Super-enhancer-driven MLX mediates redox balance maintenance via SLC7A11 in osteosarcoma[J]. Cell Death Dis, 2023, 14(7): 439. DOI: 10.1038/s41419-023-05966-y. pmid: 37460542
[10]	Nie JB, Ling YH, Jin MC, et al. Butyrate enhances erastin-induced ferroptosis of osteosarcoma cells via regulating ATF3/SLC7A11 pathway[J]. Eur J Pharmacol, 2023, 957: 176009. DOI: 10.1016/j.ejphar.2023.176009.
[11]	Liu Q, Wang KZ. The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin[J]. Cell Biol Int, 2019, 43(11): 1245-1256. DOI: 10.1002/cbin.11121. pmid: 30811078
[12]	Kirtonia A, Sethi G, Garg M. The multifaceted role of reactive oxygen species in tumorigenesis[J]. Cell Mol Life Sci, 2020, 77(22): 4459-4483. DOI: 10.1007/s00018-020-03536-5.
[13]	Gan BY. ACSL4, PUFA, and ferroptosis: new arsenal in anti-tumor immunity[J]. Signal Transduct Target Ther, 2022, 7(1): 128. DOI: 10.1038/s41392-022-01004-z.
[14]	Qiu C, Liu TY, Luo D, et al. Novel therapeutic savior for osteosarcoma: the endorsement of ferroptosis[J]. Front Oncol, 2022, 12: 746030. DOI: 10.3389/fonc.2022.746030.
[15]	Ge ZY, Song DL. A five ferroptosis-related genes risk score for prognostic prediction of osteosarcoma[J]. Medicine (Baltimore), 2022, 101(50): e32083. DOI: 10.1097/MD.0000000000032083.
[16]	Zhang YX, Li SY, Li FZ, et al. High-fat diet impairs ferroptosis and promotes cancer invasiveness via downregulating tumor suppressor ACSL4 in lung adenocarcinoma[J]. Biol Direct, 2021, 16(1): 10. DOI: 10.1186/s13062-021-00294-7. pmid: 34053456
[17]	Lee H, Zandkarimi F, Zhang YL, et al. Energy-stress-mediated AMPK activation inhibits ferroptosis[J]. Nat Cell Biol, 2020, 22(2): 225-234. DOI: 10.1038/s41556-020-0461-8. pmid: 32029897
[18]	Zhu YR, Zhang XY, Wu QP, et al. PF-06409577 activates AMPK signaling and inhibits osteosarcoma cell growth[J]. Front Oncol, 2021, 11: 659181. DOI: 10.3389/fonc.2021.659181.
[19]	Liu W, Zhao YC, Wang GF, et al. TRIM22 inhibits osteosarcoma progression through destabilizing Nrf2 and thus activation of ROS/AMPK/mTOR/autophagy signaling[J]. Redox Biol, 2022, 53: 102344. DOI: 10.1016/j.redox.2022.102344.
[20]	Wang DY, Wu YN, Huang JQ, et al. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance[J]. Chin J Cancer, 2016, 35: 47. DOI: 10.1186/s40880-016-0109-z.
[21]	Battaglia AM, Chirillo R, Aversa I, et al. Ferroptosis and cancer: mitochondria meet the "iron maiden" cell death[J]. Cells, 2020, 9(6): 32575749. DOI: 10.3390/cells9061505.
[22]	Han ST, Lin FY, Qi YC, et al. HO-1 contributes to luteolin-triggered ferroptosis in clear cell renal cell carcinoma via increasing the labile iron pool and promoting lipid peroxidation[J]. Oxid Med Cell Longev, 2022, 2022: 3846217. DOI: 10.1155/2022/3846217.
[23]	Li XJ, Liu JY. FANCD2 inhibits ferroptosis by regulating the JAK2/STAT3 pathway in osteosarcoma[J]. BMC Cancer, 2023, 23(1): 179. DOI: 10.1186/s12885-023-10626-7. pmid: 36814203
[24]	Bersuker K, Hendricks JM, Li ZP, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis[J]. Nature, 2019, 575(7784): 688-692. DOI: 10.1038/s41586-019-1705-2.
[25]	Kraft VAN, Bezjian CT, Pfeiffer S, et al. GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling[J]. ACS Cent Sci, 2020, 6(1): 41-53. DOI: 10.1021/acscentsci.9b01063.
[26]	Mao C, Liu XG, Zhang YL, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer[J]. Nature, 2021, 593(7860): 586-590. DOI: 10.1038/s41586-021-03539-7.
[27]	Luo Y, Gao X, Zou LT, et al. Bavachin induces ferroptosis through the STAT3/P53/SLC7A11 axis in osteosarcoma cells[J]. Oxid Med Cell Longev, 2021, 2021: 1783485. DOI: 10.1155/2021/1783485.
[28]	Liu JY, Lou CG, Zhen CX, et al. Iron plays a role in sulfasalazine-induced ferroptosis with autophagic flux blockage in K7M2 osteosarcoma cells[J]. Metallomics, 2022, 14(5): mfac027. DOI: 10.1093/mtomcs/mfac027.
[29]	Lv HH, Zhen CX, Liu JY, et al. β-Phenethyl isothiocyanate induces cell death in human osteosarcoma through altering iron metabolism, disturbing the redox balance, and activating the MAPK signaling pathway[J]. Oxid Med Cell Longev, 2020, 2020: 5021983. DOI: 10.1155/2020/5021983.
[30]	Lv HH, Zhen CX, Liu JY, et al. PEITC triggers multiple forms of cell death by GSH-iron-ROS regulation in K7M2 murine osteosarcoma cells[J]. Acta Pharmacol Sin, 2020, 41(8): 1119-1132. DOI: 10.1038/s41401-020-0376-8.
[31]	Fan Q, Zhan XL, Xiao ZM, et al. Phenethyl isothiocyanate enhances adriamycin-induced apoptosis in osteosarcoma cells[J]. Mol Med Rep, 2015, 12(4): 5945-5950. DOI: 10.3892/mmr.2015.4187.
[32]	De Vico G, Martano M, Maiolino PL, et al. Expression of transferrin receptor-1 (TFR-1) in canine osteosarcomas[J]. Vet Med Sci, 2020, 6(3): 272-276. DOI: 10.1002/vms3.258. pmid: 32239803
[33]	Salaroli R, Andreani G, Bernardini C, et al. Anticancer activity of an Artemisia annua L. hydroalcoholic extract on canine osteosarcoma cell lines[J]. Res Vet Sci, 2022, 152: 476-484. DOI: 10.1016/j.rvsc.2022.09.012. pmid: 36156377
[34]	Chen M, Jiang YH, Sun YB. KDM4A-mediated histone demethy-lation of SLC7A11 inhibits cell ferroptosis in osteosarcoma[J]. Biochem Biophys Res Commun, 2021, 550: 77-83. DOI: 10.1016/j.bbrc.2021.02.137.
[35]	Xu WN, Yang RZ, Zheng HL, et al. NDUFA4L2 regulated by HIF-1α promotes metastasis and epithelial-mesenchymal transition of osteosarcoma cells through inhibiting ROS production[J]. Front Cell Dev Biol, 2020, 8: 515051. DOI: 10.3389/fcell.2020.515051.
[36]	马小平, 常君丽, 孙星媛, 等. 长非编码RNA调控骨肉瘤耐药机制的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 51-54. DOI: 10.3760/cma.j.cn371439-20221005-00010.
[37]	Liu YF, Zhang ZM, Li Q, et al. Mitochondrial APE1 promotes cisplatin resistance by downregulating ROS in osteosarcoma[J]. Oncol Rep, 2020, 44(2): 499-508. DOI: 10.3892/or.2020.7633. pmid: 32627008
[38]	Zhang YN, Shen GH, Meng TT, et al. Eicosapentaenoic acid enhances the sensitivity of osteosarcoma to cisplatin by inducing ferroptosis through the DNA-PKcs/AKT/NRF2 pathway and reducing PD-L1 expression to attenuate immune evasion[J]. Int Immunopharmacol, 2023, 125(Pt B): 111181. DOI: 10.1016/j.intimp.2023.111181.
[39]	Liu L, Geng H, Mei CJ, et al. Zoledronic acid enhanced the antitumor effect of cisplatin on orthotopic osteosarcoma by ROS-PI3K/Akt signaling and attenuated osteolysis[J]. Oxid Med Cell Longev, 2021, 2021: 6661534. DOI: 10.1155/2021/6661534.
[40]	Tang Z, Dong H, Li T, et al. The synergistic reducing drug resistance effect of cisplatin and ursolic acid on osteosarcoma through a multistep mechanism involving ferritinophagy[J]. Oxid Med Cell Longev, 2021, 2021: 5192271. DOI: 10.1155/2021/5192271.

铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展

Research progress on the molecular mechanism and related treatments of ferroptosis in osteosarcoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 40

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[2]	刘小洁, 黄俊星. NADPH氧化酶2在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(10): 618-621.
[3]	马小平, 常君丽, 孙星媛, 杨燕萍. 长非编码RNA调控骨肉瘤耐药机制的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 51-54.
[4]	肖楠, 孙鹏飞. 氧化应激在胶质瘤放化疗敏感性中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 357-361.
[5]	杨娅, 宁晓飞, 李炳亮, 姚慧, 山长平, 吕敏. 原花青素通过诱导活性氧产生介导抗SNU-1胃癌细胞株的作用机制研究[J]. 国际肿瘤学杂志, 2022, 49(5): 257-262.
[6]	周仁邦, 张仲传, 许志远, 朱勋兵. miR-219a-5p通过负调控HMGA2抑制骨肉瘤U2OS细胞增殖、侵袭和迁移[J]. 国际肿瘤学杂志, 2022, 49(4): 193-198.
[7]	曾艳, 罗盼, 王子琪, 吴伟莉. 药物在头颈部肿瘤治疗中引起铁死亡的作用机制[J]. 国际肿瘤学杂志, 2022, 49(3): 173-176.
[8]	周欣宇, 贾秀红. 铁死亡在白血病治疗中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(12): 759-762.
[9]	张永丽, 张若佳, 范焕彩, 葛鲁娜, 王林. TXNDC5-Prx2途径对前列腺癌细胞耐药性的调控[J]. 国际肿瘤学杂志, 2021, 48(8): 473-478.
[10]	李炳亮, 杨娅, 黄英丽, 司文, 李兴伟, 张元民, 卞继超, 陈语. miR-20a-5p靶向KDM6B对骨肉瘤细胞增殖、迁移和侵袭能力的影响[J]. 国际肿瘤学杂志, 2021, 48(2): 65-73.
[11]	施玥, 李晟, 冯继锋. 急腹症风险下转移灶不可切除结直肠癌原发灶的处理方式选择[J]. 国际肿瘤学杂志, 2021, 48(11): 693-697.
[12]	徐一月, 赵少荣, 刘晶晶, 张瑾. 细胞铁死亡调控机制及其在乳腺癌治疗中的意义[J]. 国际肿瘤学杂志, 2020, 47(6): 372-376.
[13]	杨怡婷, 程忠平. 炎症细胞因子在卵巢上皮癌化疗耐药中的作用[J]. 国际肿瘤学杂志, 2020, 47(4): 249-251.
[14]	衣琳, 邱实. 紫草素抗胶质瘤效应及其作用机制[J]. 国际肿瘤学杂志, 2019, 46(8): 489-491.
[15]	何剑波, 宁瑞玲, 蒋玮, 刘乾飞, 曾爱屏. 重组人血管内皮抑制素优化给药策略联合化疗治疗晚期野生型NSCLC的临床观察[J]. 国际肿瘤学杂志, 2019, 46(8): 509-512.